Tag: GlobeNewswire

HERNDON, Va., Oct. 07, 2026 (GLOBE NEWSWIRE) — Navient (Nasdaq: NAVI) will host an audio webcast to review its third quarter 2026 results on Wednesday, November 4, 2026, at 5:00 p.m. Eastern Time.

The webcast will be available on Navient.com/investors; a replay of the webcast will be available on the site.

The results will be posted the same day on Navient.com/investors after 4:00 p.m. Eastern Time before the call begins.

In addition to being available on the company’s investor website, the results will be filed with the SEC on a Form 8-K available at SEC.gov.

About Navient
Navient (Nasdaq: NAVI) creates long-term value for customers and investors with responsible lending, flexible refinancing, trusted servicing oversight, and decades of education finance and portfolio management expertise. Through our Earnest business, we help customers confidently achieve financial success through digital financial services. Our employees thrive in a culture of belonging, where they are supported and proud to deliver meaningful outcomes. Learn more on Navient.com.

Contact:
Media: Cate Fitzgerald, 703-831-6347, catherine.fitzgerald@navient.com
Investors: Micah Andrews, 571-415-5413, micah.andrews@navient.com
Roger Yankoupe, 571-592-8569, roger.yankoupe@navient.com

ATHENS, Greece, Oct. 07, 2026 (GLOBE NEWSWIRE) — TOP Ships Inc. (the “Company” or “TOP Ships”) (NYSE American: TOPS), an international owner and operator of modern, fuel-efficient “ECO” tanker vessels, announced today that it has entered into a share purchase agreement with a related party (the “Seller”) to purchase the shares of four companies (the “SPVs”) which have entered into shipbuilding contracts with Guangzhou Shipyard International Company Limited for the construction of four high-specification, ECO, ice class 1A MR Product Tankers to be delivered between June 2029 and March 2030.

The SPVs are finalizing lease financing agreements (the “Financings”), arranged by the Seller with a major Chinese leasing company, covering approximately 85% of all shipbuilding installments.

The SPVs have secured time charter employment for the vessels with an Oil Major, commencing upon their respective deliveries, for a firm duration of seven years, with the charterer holding options to extend for up to three additional years. The total potential gross revenue backlog from these contracts, assuming the exercise of all available charter extension options, is approximately $316.9 million.

The aggregate purchase price for 100% of the issued shares of the SPVs is approximately $34.95 million (the “Consideration”) and is payable by 31 December 2026. The closing of the transaction is subject to customary closing conditions and the successful conclusion of the Financings by the Seller.

The acquisition was approved by a special committee consisting of independent and disinterested members of the Company’s board of directors, which obtained a fairness opinion with respect to the Consideration from an independent financial advisor.

The Company’s CEO said:

“Today’s deal is consistent with our recently announced redeployment of capital into our core tanker business, while at the same time further expanding our ice class fleet to 7 vessels and diversifying our charterer base with the addition of another oil major. These four high-specification, ice class vessels enhance the trading flexibility of our fleet, and their seven-year firm charters provide long-term contracted employment with a first-class counterparty well into the next decade. The total potential gross revenue backlog from these four newbuilding MR tankers, assuming the exercise of all available charter extension options, is approximately $317 million. Upon closing of this transaction, the total potential gross revenue backlog, from our fourteen newbuilding MR tankers, assuming the exercise of all available charter extension options, will be approximately $997 million. Including contracted time charters for our operating fleet and our 50% proportionate share of the backlog attributable to our JV vessels, total potential gross revenue backlog —including optional periods—will increase to approximately $1.24 billion, demonstrating the strength and visibility of our future potential cash flows. We remain focused on building a modern, high-specification fleet, with approximately 85% of the shipbuilding installments financed, employed on long-term charters with leading energy companies and traders, which we believe enhances the stability of our future revenue streams and positions the Company well for the next chapter of its development.”

About the Company
TOP Ships Inc. is an international owner and operator of ocean-going vessels focusing on modern, fuel-efficient eco tanker vessels transporting crude oil, petroleum products (clean and dirty) and bulk liquid chemicals. The Company’s tanker operating fleet has a total capacity of 857,000 dwt and consists of one 50,000 dwt product/chemical tanker, one 157,000 dwt Suezmax tanker, two 300,000 dwt VLCCs and, through a joint venture, 50% interests in two 50,000 dwt product tankers. The Company has entered into newbuilding contracts for ten 50,000 dwt MR newbuilding tankers scheduled for delivery from the second quarter of 2028 through the fourth quarter of 2029. In addition, the Company has entered into a share purchase agreement to acquire four shipowning companies that have entered into newbuilding contracts for four high-specification 50,000 dwt MR newbuilding tankers scheduled for delivery from the second quarter of 2029 through the first quarter of 2030, with closing being subject to customary closing conditions and the successful conclusion of the Financings by the Seller. The Company also owns the megayacht M/Y Para Bellvm, which it has announced its intention to divest. The Company is incorporated under the laws of the Republic of the Marshall Islands and has executive offices in Athens, Greece. Its common shares trade on the NYSE American under the symbol “TOPS”. For more information about TOP Ships Inc., visit its website: www.topships.org.

For further information please contact:
Alexandros Tsirikos

Chief Financial Officer

TOP Ships Inc.

Tel: +30 210 812 8107

Email: atsirikos@topships.org

Forward-Looking Statements
Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts, including statements regarding future revenues and cash flows, potential gross revenue backlog, redeployment of capital, the acquisition of the SPVs and the expected timing of its closing, the expected delivery of the newbuilding vessels, the commencement of, and the declaration of optional periods under, the related time charters, the availability of financing for the newbuilding vessels, the intended divestment of the M/Y Para Bellvm, and the Company’s future fleet, business strategy and prospects.

The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “plan,” “potential,” “may,” “should,” “expect” “pending” and similar expressions identify forward-looking statements. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections. Please see the Company’s filings with the Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties. The information set forth herein speaks only as of the date hereof, and the Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication.

CEO interview explores Ampligen’s potential to extend survival and improve quality of life as AIM advances toward pivotal development

Access the article here

OCALA, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today spotlighted a BioTuesdays feature examining the Company’s strategy to address the critical treatment gap of maintaining disease control after first-line chemotherapy for metastatic pancreatic cancer. The article features an interview with AIM Chief Executive Officer Thomas K. Equels and explores the scientific and clinical foundation supporting Ampligen®’s (rintatolimod) potential as a pancreatic cancer maintenance therapy.

Read the full BioTuesdays article, “AIM advancing immunology solutions for globally important diseases”

The feature examines Ampligen’s potential to convert the immunosuppressive tumor microenvironment, turning “cold” tumors into a more immunologically active state and thus enabling checkpoint inhibitors to work more effectively. This approach is being evaluated in a clinical trial of Ampligen in combination with AstraZeneca’s Imfinzi® (durvalumab) following first-line chemotherapy (the “DURIPANC” trial). With final Ampligen dosing complete, AIM is working toward the next stage of clinical development as it awaits the reporting of primary and secondary endpoints.

“For patients with metastatic pancreatic cancer, extending survival and improving quality of life are the outcomes that matter most,” said AIM Chief Executive Officer Thomas K. Equels. “The BioTuesdays feature captures why we are pursuing Ampligen in this setting: the urgent need for an effective maintenance therapy and the potential to address the immune resistance that makes pancreatic cancer so difficult to treat. With Ampligen dosing complete, our focus is on translating the anticipated clinical findings and biomarker research into a path toward pivotal development. Our mission is to give patients more time, better quality of life and hope.”

BioTuesdays also examines encouraging survival and quality-of-life observations from AIM’s Netherlands-approved Named Patient Program, which provided Ampligen to patients with pancreatic cancer following FOLFIRINOX. Exploratory analyses identified patient subgroups with favorable survival observations based on immune and tumor biomarkers. The segment also highlights observations from a Dutch Named Patient Program (NPP) in which patients with radiologically stable pancreatic cancer after FOLFIRINOX received Ampligen as a maintenance treatment. In an exploratory analysis of 39 patients with a neutrophil-to-lymphocyte ratio (“NLR”) below 4.5, median overall survival was 34.8 months, measured from the start of FOLFIRINOX. This encouraging observation supports further investigation of Ampligen following chemotherapy. These findings are informing AIM’s efforts to better understand patient response and guide future trial design. The Named Patient Program was not a controlled clinical trial, and comparisons with historical controls do not establish treatment efficacy.

The article brings together the clinical observations, mechanism of action and biomarker research underpinning AIM’s pancreatic cancer strategy. It also discusses the Company’s patents covering Ampligen in combination with checkpoint inhibitors, pancreatic cancer orphan drug designations in the United States and European Union, and potential financing or pharmaceutical partnership pathways to support a pivotal Phase 3 study.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. Any forward-looking statements set forth in this press release speak only as of the date hereof. Such forward-looking statements may include statements relating, but not limited to: the potential of Ampligen to address immune resistance in pancreatic cancer through its immune-modulating activity; the potential of Ampligen in combination with AstraZeneca’s Imfinzi (durvalumab) in the Phase 2 DURIPANC clinical trial; and the timing and outcome of the DURIPANC topline results; the Company’s long-term pancreatic cancer development strategy and its efforts to position Ampligen for the next stage of development; and the Company’s ability to create long-term value for its stockholders. Forward-looking statements include statements attributed to, or made by, the Company’s Chief Executive Officer in this press release. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact, including statements regarding the potential of Ampligen’s mechanism of action, anticipated regulatory milestones, our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. Words such as “believe,” “may,” “might,” “will,” “could,” “should,” “can,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “envision,” “potential” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in preclinical studies do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

For a detailed discussion of these and other risk factors, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. These filings are available at www.sec.gov and www.aimimmuno.com. You should not place undue reliance on any forward-looking statements. The information found on the Company’s website or on other websites referenced or linked to in this press release is not incorporated by reference into this press release and such information is referenced or linked for reference purposes only.

CONTACT: Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

Company to demonstrate 360° vehicle situational awareness and beyond-line-of-sight drone capabilities following recent commercial momentum across land and airborne defense applications

Rehovot, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a global leader in edge computing, artificial intelligence (“AI”), and video intelligence solutions for defense applications, today announced that it will participate in the AUSA 2026 Annual Meeting and Exposition, taking place October 12-14, 2026, at the Walter E. Washington Convention Center in Washington, D.C., where the Company is scheduled to showcase and demonstrate a broad portfolio of edge video and AI solutions for armored vehicles, unmanned platforms and other mission-critical defense applications at Booth #761.

At AUSA, Maris-Tech will conduct live demonstrations illustrating how its edge video technology can extend situational awareness around and beyond an armored vehicle. The demonstrations will include full-perimeter, 360° vision around a vehicle while operating with the hatch closed, as well as an unmanned aerial extension that carries the same real-time visual awareness beyond the vehicle’s line of sight.

The demonstrations highlight Maris-Tech’s approach to processing video and AI directly at the edge. The Company’s technology is designed to acquire and process multiple sensor feeds, perform onboard AI analytics, and distribute low-latency video, providing operators with actionable visual information while reducing dependence on external processing infrastructure.

Maris-Tech will also display a broad selection of its edge computing and video platforms at the event. The exhibit will include solutions for armored vehicle situational awareness and thermal observation, including the Diamond Ultra and Peridot product families; AI and video processing platforms from the Jupiter family; solutions designed for drone and unmanned applications; and additional video encoding, recording, and communications technologies, including Opal, Amethyst, Mars RF, and Coral.

Maris-Tech’s participation at AUSA follows a period of significant commercial activity for the Company across multiple defense markets. In September 2026, Maris-Tech announced its largest-ever contract, a US$10 million order to develop and supply advanced video systems for multiple next-generation manned airborne platforms. The multi-year project includes additional purchase options that, if exercised in full, could bring the total value of orders received by Maris-Tech under the project to approximately US$14.1 million.

The Company also recently announced a pilot order, received through a distributor, from a leading global defense company for an armored vehicle situational awareness application. The pilot followed an extensive adaptation process in which Maris-Tech’s Jupiter product line was tailored to meet the end customer’s specific video streaming requirements. Based on estimates and forecasts provided by the end customer, successful completion of the pilot could result in significant follow-on orders over the coming years.

“We see AUSA as an important opportunity to demonstrate how the technologies behind the Company’s recent commercial progress translate into operational capabilities across multiple defense platforms,” said Israel Bar, Chief Executive Officer of Maris-Tech. “From 360° situational awareness on armored vehicles to airborne and unmanned applications, our focus is on delivering edge video and AI technologies that address real operational requirements. We look forward to demonstrating these capabilities to customers and partners in Washington.”

AUSA 2026
October 12–14, 2026
Walter E. Washington Convention Center
Washington, D.C.
Maris-Tech Booth #761

About Maris-Tech Ltd.

Maris-Tech delivers AI-powered edge video solutions for mission-critical defense and security operations, enabling real-time situational awareness, intelligence gathering, and surveillance in bandwidth- and latency-constrained environments. Trusted by leading security organizations, Maris-Tech platforms are deployed across UAVs, UGVs, armored vehicles, and dismounted soldier systems, supporting missions that require ultra-low-latency video processing and onboard AI analytics. From intelligence collection in extreme conditions to AI-driven surveillance and terrain dominance, Maris-Tech masters the AI video pipeline at the edge through best-in-class SWaP-optimized, ruggedized computing solutions.

For more information, visit https://www.maris-tech.com/

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may”, “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when it is discussing its planned participation in AUSA 2026 and the products and technologies it expects to showcase and demonstrate at the event; the capabilities and potential applications of its products and technologies; the potential for successful completion of the pilot to result in significant follow-on orders over the coming years; the potential for Maris-Tech to receive additional orders under the multi-year airborne platform project if the applicable purchase options are exercised; and the Company’s expectations regarding opportunities for its technologies across armored vehicle, airborne and unmanned applications. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: its ability to successfully market its products and services, including in the United States; the acceptance of its products and services by customers; its continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; its ability to successfully develop new products and services; its success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; its ability to comply with applicable regulations; and the other risks and uncertainties described in the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on May 15, 2026, and its other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations:

Nir Bussy, CFO
Tel: +972-72-2424022
Nir@maris-tech.com

5 October 2026

Notification no. 78/2026

Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation.

In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata.

For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

Contact: Stefan Kailay Wind, Nordic Head of Media Relations, tel. +45 45 14 14 00

Attachment

• APMH Invest AS – sale – 2026 10 02

VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or “the Company”), a commercial-stage pharmaceutical manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced that it will participate in the ThinkEquity Conference taking place on October 15, 2026, at the Mandarin Oriental Hotel in New York City. Management will present a corporate overview at 4:00 p.m. Eastern time and will be available for one-on-one meetings with investors registered for the event.

Investors interested in scheduling a meeting with Optimi management should contact their ThinkEquity representative or register for the conference here.

About Optimi Health Corp.

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on developing, manufacturing, and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

For more information, please visit optimi.net.

For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca

Investor Relations Contact:
ir@optimi.net
CORE IR

Forward-Looking Statements

This press release may contain forward-looking statements and forward-looking information within the meaning of applicable securities laws. Future results may differ materially from those expressed or implied in any forward-looking statement. Forward-looking statements and forward-looking information are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “estimates,” “may,” “will,” “would,” “could,” or similar expressions. In this news release, forward-looking statements and forward-looking information relate to, among other things, information regarding: the Company’s participation in the ThinkEquity Conference and availability for one-on-one meetings with investors. Forward-looking statements and forward-looking information are based on several assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. These risk factors include, among other things, market acceptance of the Company’s products, as well as those described under “Risk Factors” in the Company’s registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time which are available at www.sec.gov and on SEDAR+ at www.sedarplus.com and in the Company’s continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.com. Forward-looking statements reflect current expectations of management regarding future events and speak only as of the date of this press release. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

• Pyrolysis-to-Power Process Converts Low-Value Forest Wood into Firm, Renewable Electricity
• Technology Produces Dispatchable Power Without Dependence on Wind or Sunlight

Fort Lauderdale, FL, Oct. 07, 2026 (GLOBE NEWSWIRE) — Algorhythm Holdings, Inc. (the “Company”) (NASDAQ: RIME) – a diversified holding company that owns and operates Azure Holdings, a renewable power plant developer, and SemiCab, an AI enabled logistics provider, today introduced Azure P2P^™, the pyrolysis-to-power process at the center of its recently acquired Azure Holdings business.

Azure P2P^™ is designed to convert low-value forest wood into renewable electricity capable of operating around the clock. Unlike intermittent renewable resources that depend on weather conditions, Azure P2P^™ uses renewable biomass as a continuously available fuel source, enabling power generation when customers need it.

The technology is being developed for large-scale power consumers, including data centers, utilities and industrial facilities where access to reliable power has become an increasingly important infrastructure requirement.

From Forest Residuals to Renewable Power

Azure P2P^™ begins with wood chips derived from lower-value portions of working forests, including tops, limbs, thinnings and other low-grade wood.

The process occurs in five primary stages:

1. Wood In: Low-grade forest material is processed into chips and delivered to the plant.
2. Drying: The chips are dried to a controlled moisture content. Water removed during this stage is captured as part of the process, creating an additional resource and potential revenue stream.
3. Conversion: The dried material enters a sealed, zero-oxygen chamber where heat breaks down the wood without burning it.
4. Syngas and Biochar: The conversion process produces syngas, a clean fuel gas, and biochar, a solid carbon co-product.
5. Power Generation: The syngas is combusted to raise steam, which drives turbines to generate electricity.

The result is renewable electricity that does not depend on wind or sunlight and can be available whenever customers require it up to 99.9999% uptime.

Firm, Renewable Power

The ability to generate power continuously is central to Azure P2P^™. Working forests regenerate the biomass used as feedstock, while the process itself does not depend on real-time weather conditions. The result is a renewable power source designed to operate around the clock.

Management believes this combination of renewability and dispatchability makes Azure P2P^™ particularly well suited for data centers, advanced manufacturing facilities and other power-intensive operations requiring high levels of reliability.

“Renewable power is increasingly important, but for large-scale power consumers, reliability is equally critical,” said Andrew Thompson, Chief Executive Officer of Algorhythm Holdings. “A data center cannot simply stop operating when the sun sets or the wind stops blowing. Azure P2P^™ is designed to address both sides of that equation by providing renewable power from a fuel source capable of supporting continuous generation.”

Creating Value from an Underutilized Resource

Azure P2P^™ is designed to utilize forest materials with limited traditional commercial uses, including tops, limbs, thinnings and other low-grade wood rather than higher-value sawlogs used to manufacture lumber.

Creating commercial use for this material can also support active forest management. Thinning crowded stands gives remaining trees additional room to grow and removes material that can contribute to wildfire risk.

U.S. Forest Service Chief Tom Schultz recently highlighted the importance of these practices, stating that “Active forest management remains essential to creating resilient, productive forests,” during testimony before the House Agriculture Committee on July 22, 2026.

About Algorhythm Holdings

Algorhythm Holdings, Inc. is a holding company with two primary assets, Azure Holdings and SemiCab Holdings. Azure Holdings, dba Azure Energy (“Azure”), is a developer of renewable biomass power generation infrastructure. Its team, including its co-founders, consists of some of the most experienced biomass power plant experts in the U.S. today. Collectively, this team has designed and built 72 facilities generating 17.5 GW of renewable power to date. Azure was launched in 2025 and has already secured equity participation, which management estimates to have a net present value of over $220 million, in multiple power plants currently under construction in the U.S. Azure has significant fee-based consulting revenues under multi-year contracts and is generating positive EBITDA. For additional information, please go to: http://www.azure-energy.co.

Algorhythm Holdings, Inc. also owns and operates SemiCab, an AI-enabled logistics software provider. Since 2020, SemiCab has enabled major retailers, brands and transportation providers to address common supply-chain problems globally. Its AI-enabled, cloud-based Collaborative Transportation Platform is designed to provide the scalability required to predict and optimize millions of loads and hundreds of thousands of trucks. SemiCab uses real-time data from API-based load tendering and pre-built integrations with TMS and ELD partners to orchestrate collaboration across manufacturers, retailers, distributors, and their carriers. SemiCab uses AI/ML predictions and advanced predictive optimization models to enable fully loaded round trips. With SemiCab’s AI platform, shippers pay less and carriers make more without having to change a thing. For additional information, please go to: http://www.semicab.com.

Investor Relations Contact

Brendan Hopkins
407-645-5295
investors@algoholdings.com
www.algoholdings.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “expects,” “anticipates,” “believes,” “will,” “will likely result,” “will continue,” “plans to,” “potential,” “promising,” and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described from time to time in the Company’s reports filed with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this press release. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this press release to conform our statements to actual results or changed expectations, or as a result of new information, future events or otherwise.

SUNNYVALE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the upcoming presentation of a scientific poster entitled “Cardiac Delivery of Autologous Minimally Processed Cell Therapy in HFrEF: Multicenter, Double Blind RCT (CardiAMP HF II)” at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026.

The presentation includes details on the design and scientific support for the CardiAMP™ HF II Study. The objective of the study is to determine efficacy of high dose autologous cell treatment for patients with ischemic heart failure of reduced ejection fraction (HFrEF), who are on guideline directed medical therapy but still exhibit undesirable elevated biomarkers of heart stress. This presentation will become available through the Scientific Publications on BioCardia’s website.

FDA has approved a category B designation for CardiAMP cell therapy system in three separate clinical trials as they determined either the underlying questions of safety and effectiveness of the device type have been resolved or the device type can be safe and effective. FDA recently agreed that the ongoing CardiAMP HF II trial, the focus of the HFSA scientific presentation, may be sufficient to support FDA approval.

“In parallel to ongoing regulatory submissions with FDA and Japan’s PMDA related to our therapy, we are advancing the confirmatory CardiAMP HF II trial with world class centers,” said Peter Altman, PhD, BioCardia President and CEO, and member of HFSA. “At the HFSA Annual Scientific meeting this weekend we have scheduled meetings with leaders in heart failure care to discuss the evidence supporting this therapy and collaborative efforts to provide this new therapeutic option to patients who have plateaued on available therapies and may benefit from minimally invasive autologous cell therapy.”

About BioCardia

BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph^® vascular navigation product platforms, and soon the Heart3D™ fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies. For more information, visit www.biocardia.com.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, statements relating to the presentation and meetings planned at HFSA.

These forward-looking statements are made as of the date of this press release. We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release.

Factors that could cause or contribute to such differences include, but are not limited to, the Company’s liquidity position and its ability to raise additional funds, as well as the Company’s ability to successfully progress its clinical trials and regulatory programs. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 24, 2026, under the caption titled “Risk Factors” and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Media Contact:
Miranda Peto, Investor Relations
Email: mpeto@BioCardia.com
Phone: 650-226-0120

Investor Contact:
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) — Lucas GC Limited (NASDAQ: LGCL) (“Lucas” or the “Company”), an artificial intelligence (the “AI”) technology-driven Platform-as-a-Service (the “PaaS”) company, applying such technologies in human resources and insurance industry verticals today announced its financial results for 1H fiscal year of 2026.

1H 2026 Financial Highlights

• Our revenue was RMB245.3 million (US$35.7 million) for the six months ended June 30, 2026, compared with RMB386.9 million for the six months ended June 30, 2025, representing a decrease of 36.6%.
• We recorded a gross margin of 35.4% for the six months ended June 30, 2026, representing an increase of 1.7% compared with that of the six months ended June 30, 2025.
• We recorded net income of RMB19.9 million (US$2.9 million) for the six months ended June 30, 2026, compared with RMB21.5 million for the six months ended June 30, 2025.
• Our net income margin increased to 8.0% for the six months ended June 30, 2026, compared with 5.5% for the six months ended June 30, 2025.

Management Commentary

Howard Lee, Chief Executive Officer of Lucas, said: “Our first-half performance highlights the success of our ongoing pivot from providing traditional service into higher value-added technology services. While macroeconomic headwinds in China and our strategic shift from lower-margin contracts impacted top-line revenue, our focus on higher-margin product lines and expansion delivered remarkable bottom-line expansion. In return, our gross margin expanded by 1.7% to 35.4%, while net income decreased slightly by 7.6% year-over-year to RMB19.9 million, with a net margin of 8.0%.”

Comparison of Interim Financial Results for the six months ended June 30, 2025 and 2026

The following table summarizes the results of our operations during the six months ended June 30, 2025 and 2026, respectively, and provides information regarding the dollar and percentage increase or (decrease) during such periods.

		For the Period Ended June 30,															Variance
		2025						2026									Amount			Percentage
		RMB			%			RMB			US$			%			RMB			%
		(In thousands, except percentages)
Total revenues		386,890			100.0			245,285			35,744			100.0			(141,605	)		(36.6	)
Cost of revenues		(256,355	)		(66.3	)		(158,392	)		(23,081	)		(64.6	)		(97,963	)		(38.2	)
Gross profit		130,535			33.7			86,893			12,663			35.4			(43,642	)		(33.4	)
Operating expenses
Selling and marketing expenses		(30,562	)		(7.9	)		(19,204	)		(2,798	)		(7.8	)		(11,358	)		(37.2	)
General and administrative expenses		(38,798	)		(10.0	)		(17,807	)		(2,595	)		(7.3	)		(20,991	)		(54.1	)
Research and development expenses		(45,881	)		(11.9	)		(24,017	)		(3,500	)		(9.8	)		(21,864	)		(47.7	)
Total operating expenses		(115,241	)		(29.8	)		(61,028	)		(8,893	)		(24.9	)		(54,213	)		(47.0	)
Income from operations		15,294			3.9			25,865			3,770			10.5			10,571			69.1
Other income (expenses)
Financial expenses, net		(325	)		(0.1	)		(1,402	)		(204	)		(0.6	)		1,077			331.4
Other (expenses) income, net		(89	)		(0.0	)		13			2			0.0			102			114.6
Total other expenses, net		(414	)		(0.1	)		(1,389	)		(202	)		(0.6	)		975			235.5
Income before income tax benefit (expenses)		14,880			3.8			24,476			3,568			9.9			9,596			64.5
Income tax benefit (expenses)		6,613			1.7			(4,620	)		(673	)		(1.9	)		(11,233	)		(169.9	)
Net income		21,493			5.5			19,856			2,895			8.0			(1,637	)		(7.6	)

Revenues

Our revenues decreased by approximately RMB141.6 million, or 36.6%, from RMB386.9 million for the six months ended June 30, 2025 to RMB245.3 million (US$35.7 million) for the six months ended June 30, 2026, primarily due to a decrease of revenues from outsourcing service. The following table sets forth a breakdown of our revenues, each expressed in the absolute amount and as a percentage of our total revenues, for the periods indicated:

		For the Six Months Ended June 30,															Variance
		2025						2026									Amount			Percentage
		RMB			%			RMB			US$			%			RMB			%
		(In thousands, except percentages)
Revenues:
Recruitment service		31,806			8.2			26,266			3,828			10.7			(5,540	)		(17.4	)
Outsourcing service		334,471			86.5			213,656			31,134			87.1			(120,815	)		(36.1	)
Others		20,613			5.3			5,363			782			2.2			(15,250	)		(74.0	)
Total revenues		386,890			100.0			245,285			35,744			100.0			(141,605	)		(36.6	)

Revenues from recruitment services decreased by RMB5.5 million, or 17.4%, from RMB31.8 million for the six months ended June 30, 2025 to RMB26.3 million (US$3.8 million) for the six months ended June 30, 2026. Broader macroeconomic headwinds led corporate customers to exercise caution regarding headcount growth, resulting in lower volume for traditional recruitment placements as clients increasingly favored outsourced workforce solutions.

Revenues from outsourcing services decreased by approximately RMB120.8 million, or 36.1%, from RMB334.5 million for the six months ended June 30, 2025 to RMB213.7 million (US$31.1 million) for the six months ended June 30, 2026. The decrease was primarily driven by a reduction in corporate customer demand, as customers exercised spending discipline and deferred investments in custom IT systems, process automation, and labor-optimization projects. To mitigate these top-line headwinds, management focused on optimizing our service mix by prioritizing toward higher-value technology solutions during the period.

Revenues from other services decreased by RMB15.3 million, or 74.0%, from RMB20.6 million for the six months ended June 30, 2025 to RMB5.4 million (US$0.8 million) for the six months ended June 30, 2026. The decrease was mainly due to softened demand for non-core information technology services as clients exercised budget discipline amid a challenging economic climate.

Cost of revenues

Our cost of revenues decreased by approximately RMB98.0 million, or 38.2%, from RMB256.4 million for the six months ended June 30, 2025 to RMB158.4 million (US$23.1 million) for the six months ended June 30, 2026, which was mainly due to the decrease in outsourcing service, which had higher cost. The following table sets forth a breakdown of our cost of revenues by revenue streams, expressed as an absolute amount and as a percentage of the total revenues, for the periods indicated.

		For the Six Months Ended June 30,															Variance
		2025						2026									Amount			Percentage
		RMB			%			RMB			US$			%			RMB			%
		(In thousands, except percentages)
Cost of revenues:
Recruitment service		17,873			4.6			12,708			1,852			5.2			(5,165	)		(28.9	)
Outsourcing service		224,733			58.1			142,453			20,758			58.1			(82,280	)		(36.6	)
Others		13,749			3.6			3,231			471			1.3			(10,518	)		(76.5	)
Total cost of revenues		256,355			66.3			158,392			23,081			64.6			(97,963	)		(38.2	)

Cost related to recruitment services decreased by approximately RMB5.2 million, or 28.9%, from RMB17.9 million for the six months ended June 30, 2025 to RMB12.7 million (US$1.9 million) for the six months ended June 30, 2026, primarily due to the decrease of revenues in recruitment service.

Cost related to outsourcing services decreased by approximately RMB82.3 million, or 36.6%, from RMB224.7 million for the six months ended June 30, 2025 to RMB142.5 million (US$20.8 million) for the six months ended June 30, 2026, primarily attributable to the decline in active outsourcing project volume, which reduced direct operational expenditures, including fees paid to third-party partners.

Cost related to other services decreased by approximately RMB10.5 million, or 76.5%, from RMB13.7 million for the six months ended June 30, 2025 to RMB3.2 million (US$0.5 million) for the six months ended June 30, 2026, primarily in line with the decrease in other services.

Gross profits and margin

The following table sets forth a breakdown of our gross profit, margin by revenue streams, expressed as an absolute amount and as a percentage of their corresponding revenues for the periods indicated.

		For the Six Months Ended June 30,															Variance
		2025						2026									Amount			Percentage
		RMB			%			RMB			US$			%			RMB			%
		(In thousands, except percentages)
Gross profits:
Recruitment service		13,933			3.6			13,558			1,976			5.5			(375	)		(2.7	)
Outsourcing service		109,738			28.4			71,203			10,376			29.0			(38,535	)		(35.1	)
Others		6,864			1.7			2,132			311			0.9			(4,732	)		(68.9	)
Total gross profits		130,535			33.7			86,893			12,663			35.4			(43,642	)		(33.4	)

As a result of the foregoing, we recorded a gross profit of RMB130.5 million and RMB86.9 million (US$12.7 million) for the six months ended June 30, 2025 and 2026, respectively. Moreover, our strategic transit from pursuing revenue scale expansion to driving value optimization through gross margin enhancement, attributable to slightly gross profit margin increase from 33.7% to 35.4% in 2025 and 2026, respectively.

Operating expenses

Our operating expenses decreased from RMB115.2 million for the six months ended June 30, 2025 to RMB61.0 million (US$8.9 million) for the six months ended June 30, 2026, representing a decrease of 47.0%, primarily due to the following:

General and administrative expenses

Our general and administrative expenses decreased by 54.1% from RMB38.8 million for the six months ended June 30, 2025 to RMB17.8 million (US$2.6 million) for the six months ended June 30, 2026, which was primarily due to the decrease of RMB22.6 million (US$3.3 million) in user support operation expenses, for which we were able to normalize support spending and optimizing administrative overhead.

Research and development expenses

Our research and development expenses decreased by 47.7% from RMB45.9 million for the six months ended June 30, 2025 to RMB24.0 million (US$3.5 million) for the six months ended June 30, 2026. This reduction was primarily attributable to engineering efficiencies gained from our prior-period platform investments, which reduced the need for major AI model updates during the period. We will continue allocating capital toward high-ROI technology initiatives to support long-term commercialization and margin expansion.

Selling and marketing expenses

Our selling and marketing expenses decreased by 37.2% from RMB30.6 million for the six months ended June 30, 2025 to RMB19.2 million (US$2.8 million) for the six months ended June 30, 2026, which was mainly due to our commercial strategy toward margin optimization and organic client retention. Leveraging strong recurring relationships with returning corporate customers allowed us to streamline customer acquisition expenditure while continuing to serve the high-value enterprise accounts that power our core outsourcing business.

Other income/(expenses), net

Total other expenses, net increased by 235.5% from RMB0.4 million for the six months ended June 30, 2025 to RMB1.4 million (US$0.2 million) for the six months ended June 30, 2026.

Financial expenses mainly consist of interest income and expenses, bank charges and exchange gain or loss. Our financial expenses, net increased from RMB0.3 million for the six months ended June 30, 2025 to RMB1.4 million (US$0.2 million) for the six months ended June 30, 2026 primarily due to the increased bank interest expenses from 1.0 million for the six months ended June 30, 2025 to 1.5 million for the six months ended June 30, 2026; and the increase is offset by the exchange gain, which decreased from 0.7 million for the six months ended June 30, 2025 to 0.07 million for the six months ended June 30, 2026.

Income tax benefits (expenses)

We recorded an income tax expense of RMB4.6 million (US$0.7 million) for the six months ended June 30, 2026, compared to an income tax benefit of RMB6.6 million for the six months ended June 30, 2025. This swing from a tax benefit to a tax expense was primarily attributable to the utilization of net operating loss carryforwards as profitability improved, alongside adjustments to recognized deferred tax assets associated with R&D tax credit incentives and prior-year loss carryforwards.

Net income

As a result of the foregoing, our net income decreased slightly by RMB1.6 million, from RMB21.5 million for the six months ended June 30, 2025 to RMB19.9 million (US$2.9 million) for the six months ended June 30, 2026.

Cash Flow

As of June 30, 2026, we had cash and cash equivalents of RMB10.4 million (US$1.5 million). The following table sets forth a summary of cash flows for the periods indicated:

		For the Six Months Ended June 30,									Variances
		2025			2026						Amount			Percentage
		RMB			RMB			US$			RMB			%
		(In thousands, except for percentages)
Net cash provided by operating activities		4,349			8,345			1,217			3,996			91.9
Net cash used in investing activities		(68,789	)		(309,602	)		(45,116	)		240,813			350.1
Net cash provided by financing activities		63,368			284,824			41,505			221,456			349.5
Effect of exchange rate changes on cash and cash equivalents		(507	)		(3,455	)		(405	)		2,948			581.5
Net decrease in cash and cash equivalents		(1,579	)		(19,888	)		(2,799	)		18,309			1,159.5
Cash and cash equivalents at the beginning of period		31,661			30,305			4,334			(1,356	)		(4.3	)
Cash and cash equivalents at the end of period		30,082			10,417			1,535			(19,665	)		(65.4	)

Cash flows from operating activities

For the six months ended June 30, 2026, our net cash provided by operating activities was RMB8.3 million (US$1.2 million), which was primarily attributable to (i) net income of RMB19.9 million (US$2.9 million), primarily adjusted for depreciation of software and equipment of RMB9.8 million (US$1.4 million) and provision of expected credit losses of RMB3.2 million; (ii) an increase in advances to suppliers of RMB44.5 million (US$6.5 million), primarily due to increased upfront payments made to secure critical capacity and vendor resources for ongoing IT outsourcing deployments; (iii) an increase in accounts receivable of RMB76.9 million (US$11.2 million), primarily driven by a concentration of project completions and customer billings toward the end of the second quarter for which collections remain outstanding; (iv) an increase in accounts payable of RMB74.9 million (US$10.9 million) due to the timing of vendor settlements near the end of the interim period; and (v) an increase in contract liabilities of RMB17.3 million (US$2.5 million) due to the additional cash prepayments collected from customers in advance of product delivery and milestone completions.

For the six months ended June 30, 2025, our net cash provided by operating activities was RMB4.3 million, which was primarily attributable to (i) net income of RMB21.5 million, primarily adjusted for depreciation of software and equipment of RMB5.7 million and provision of expected credit losses of RMB3.2 million; (ii) an increase in prepaid expenses and other current assets of RMB5.0 million; (iii) an increase in deferred tax assets of RMB6.6 million, driven by expanded R&D expenditure and tax loss carryforwards; and offset by (iv) a decrease in accounts receivable of RMB10.7 million, reflecting cash collections from clients on outstanding balances during the period; (v) a decrease in accounts payable of RMB18.7 million, resulting from the timely settlement and payment of outstanding vendor balances; and (vi) a decrease in contract liabilities of RMB8.1 million, primarily due to the recognition of unearned revenue as performance obligations were fulfilled for advance customer prepayments.

Investing activities

For the six months ended June 30, 2026, our net cash used in investing activities was RMB309.6 million (US$45.1 million), which was primarily due to (i) purchase of software and equipment of RMB6.6 million (US$1.0 million); (ii) purchase of research development of RMB23.6 million (US$3.4 million); and (iii) deposits for investment in partnership entities of RMB279.4 million (US$40.7 million).

For the six months ended June 30, 2025, our net cash used in investing activities was RMB68.8 million, which was primarily due to (i) purchase of software and equipment of RMB29.5 million; (ii) purchase of research development of RMB19.2 million; and (iii) deposits for investment in partnership entities of RMB21.5 million.

Financing activities

For the six months ended June 30, 2026, our net cash provided by financing activities was RMB284.8 million (US$41.5 million), which was primarily attributable to (i) proceeds from short-term borrowings of RMB47.0 million (US$6.8 million); (ii) sale of ordinary shares through private placement of RMB280.0 million (US$40.8 million); and offset by (iii) repayment of short-term borrowing of RMB44.0 million (US$6.4 million).

For the six months ended June 30, 2025, our net cash provided by financing activities was RMB63.4 million, which was primarily attributable to (i) proceeds from short-term borrowings of RMB55.0 million; (ii) sale of public shares through public offering of RMB43.6 million; offset by (iii) repayment of short-term borrowing of RMB31.7 million; (iv) payments of offering costs related to follow-on offering of RMB1.3 million; and (v) repayment to a related party of RMB2.3 million.

About Lucas GC Limited

With 24 granted U.S. and Chinese patents and over 75 registered software copyrights in AI, data analytics and blockchain technologies, Lucas GC Limited is an AI technology-driven PaaS company, applying such technologies in human resources and insurance industry verticals. For more information, please visit: www.lucasgc.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties related to market conditions. Any forward-looking statements contained in this press release speak only as of the date hereof, and Lucas GC Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For Investor Inquiries and Media Contact:

https://www.lucasgc.com/
ir@lucasgc.com
T: 818-741-0923

LUCAS GC LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (All amounts in thousands, except for share and per share data, or otherwise noted)
		As of December 31,				As of June 30,
		2025				2026
		RMB				RMB				US$
		(Audited)				(Unaudited)
ASSETS
Current assets
Cash and cash equivalents			30,305				10,417				1,535
Short-term investments			4,813				4,780				704
Accounts receivable, net			30,730				104,415				15,389
Advance to suppliers, net			156,289				200,760				29,589
Deferred offering costs			104				104				15
Prepaid expenses and other current assets			3,010				4,125				608
Total current assets			225,251				324,601				47,840
Non-current assets
Software and equipment, net			154,125				150,941				22,246
Development expenditures			34,816				58,400				8,607
Operating lease right-of-use assets, net			124				186				27
Deferred tax assets, net			19,800				15,179				2,237
Deposits for investment in partnership entities			19,721				299,134				44,088
Total non-current assets			228,586				523,840				77,205
TOTAL ASSETS			453,837				848,441				125,045
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities
Short-term borrowings			94,861				97,861				14,423
Accounts payable			35,530				110,453				16,279
Contract liabilities			2,764				20,026				2,952
Income tax payable			55				54				8
Amounts due to related parties			5,547				7,371				1,086
Operating lease liabilities, current			–				105				15
Accrued expenses and other current liabilities			977				1,992				292
Total current liabilities			139,734				237,862				35,055
Operating lease liabilities, non-current			–				81				12
Total non-current liability			–				81				12
TOTAL LIABILITIES			139,734				237,943				35,067
Shareholders’ equity
Class A Ordinary shares (US$0.0002 par value; 235,000,000 shares authorized as of December 31, 2025 and June 30, 2026; 2,792,810 shares issued and 2,790,404 shares outstanding as of December 31, 2025 and 42,792,810 shares issued and 42,790,404 shares outstanding as of June 30, 2026)			3				57				8
Class B Ordinary Shares (US$0.0002 par value; 15,000,000 shares authorized as of December 31, 2025 and June 30, 2026; nil shares issued and outstanding as of December 31, 2025 and June 30, 2026)			–				–				–
Subscription receivables			(3	)			(3	)			–
Treasury Stock			(856	)			(856	)			(126	)
Additional paid-in capital			182,968				462,914				68,226
Statutory reserve			25,836				25,836				3,808
Retained earnings			104,335				124,044				18,282
Accumulated other comprehensive loss			(998	)			(4,459	)			(657	)
Total Lucas GC Limited shareholders’ equity			311,285				607,533				89,541
Non-controlling interests			2,818				2,965				437
Total shareholders’ equity			314,103				610,498				89,978
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY			453,837				848,441				125,045

LUCAS GC LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (All amounts in thousands, except for share and per share data, or otherwise noted)
		For the six months ended June 30,
		2025				2026
		RMB				RMB				US$
		(Unaudited)				(Unaudited)
Revenues
Recruitment service			31,806				26,266				3,828
Outsourcing service			334,471				213,656				31,134
Others			20,613				5,363				782
Total revenues			386,890				245,285				35,744
Cost of revenues			(256,355	)			(158,392	)			(23,081	)
Gross profit			130,535				86,893				12,663
Operating expenses
Selling and marketing expenses			(30,562	)			(19,204	)			(2,798	)
General and administrative expenses			(38,798	)			(17,807	)			(2,595	)
Research and development expenses			(45,881	)			(24,017	)			(3,500	)
Total operating expenses			(115,241	)			(61,028	)			(8,893	)
Income from operations			15,294				25,865				3,770
Other expenses
Financial expenses net			(325	)			(1,402	)			(204	)
Other (expenses) income, net			(89	)			13				2
Total other expenses, net			(414	)			(1,389	)			(202	)
Income before income tax benefit (expenses)			14,880				24,476				3,568
Income tax benefit (expenses)			6,613				(4,620	)			(673	)
Net income			21,493				19,856				2,895
Less: net income attributable to non-controlling interests			(159	)			(147	)			(21	)
Net income attributable to Lucas GC Limited’s ordinary shareholders			21,334				19,709				2,874
Net income			21,493				19,856				2,895
Other comprehensive income:
Foreign currency translation difference, net of tax			(506	)			(3,461	)			(504	)
Total comprehensive income			20,987				16,395				2,391
Less: total comprehensive income attributable to non-controlling interests			(159	)			(147	)			(21	)
Comprehensive income attributable to Lucas GC Limited			20,828				16,248				2,370
Earnings per share for Class A and Class B ordinary shares:
Basic			10.55				0.58				0.08
Diluted			10.55				0.58				0.08
Weighted average number of Class A and Class B ordinary shares outstanding used in calculating basic and diluted earnings per share:
Basic			2,022,399				34,171,619				34,171,619
Diluted			2,022,399				34,171,619				34,171,619

LUCAS GC LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (All amounts in thousands, except for share and per share data, or otherwise noted)
		Ordinary Shares				Treasury Stock					Subscription			Additional paid-in		Statutory		Accumulated (deficit)/ Retained		Accumulated other comprehensive (loss)/			Total Lucas GC Limited shareholders’			Non- controlling		Total shareholders’
		Share		Amount		Share		Amount			receivables			capital		reserve		earnings		income			equity			interests		equity
Balance as of December 31, 2024		1,986,677		3		2,406		(856	)		(3	)		142,828		23,271		97,118		472			262,833			2,745		265,578
Net income		–		–		–		–			–			–		–		21,334		–			21,334			159		21,493
Sale of public shares through public offering, net of offering cost		803,750		–		–		–			–			40,140		–		–		–			40,140			–		40,140
Foreign currency translation		–		–		–		–			–			–		–		–		(506	)		(506	)		–		(506	)
Balance as of June 30, 2025		2,790,427		3		2,406		(856	)		(3	)		182,968		23,271		118,452		(34	)		323,801			2,904		326,705
Balance as of December 31, 2025		2,790,404		3		2,406		(856	)		(3	)		182,968		25,836		104,335		(998	)		311,285			2,818		314,103
Net income		–		–		–		–			–			–		–		19,709		–			19,709			147		19,856
Sale of ordinary shares through private placement		40,000,000		54		–		–			–			279,946		–		–		–			280,000			–		280,000
Foreign currency translation		–		–		–		–			–			–		–		–		(3,461	)		(3,461	)		–		(3,461	)
Balance as of June 30, 2026		42,790,404		57		2,406		(856	)		(3	)		462,914		25,836		124,044		(4,459	)		607,533			2,965		610,498

*The shares and per share information are presented on a retroactive basis to reflect the reorganization, the stock consolidation on October 13, 2025 and the dual-class share structure.

LUCAS GC LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (All amounts in thousands, except for share and per share data, or otherwise noted)
		For the six months ended June 30,
		2025			2026
		RMB			RMB			US$
		(Unaudited)			(Unaudited)
Cash flows from operating activities:
Net income		21,493			19,856			2,895
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		5,691			9,787			1,426
Amortization of right-of-use assets		207			26			4
Allowance for expected credit losses		3,162			3,228			470
Fair value (gains) losses on short-term investments		(18	)		33			5
Changes in operating assets and liabilities:
Accounts receivable		10,671			(76,913	)		(11,208	)
Advance to suppliers, net		1,238			(44,471	)		(6,480	)
Prepaid expenses and other current assets		(4,976	)		(1,115	)		(162	)
Deferred tax assets, net		(6,613	)		4,620			673
Accounts payable		(18,674	)		74,923			10,918
Contract liabilities		(8,063	)		17,261			2,515
Income tax payables		–			(1	)		–
Operating lease liabilities		(254	)		99			14
Accrued expenses and other current liabilities		485			1,012			147
Net cash provided by operating activities		4,349			8,345			1,217
Cash flows from investing activities:
Purchases of software and equipment		(29,494	)		(6,604	)		(962	)
Addition to development expenditures		(19,200	)		(23,585	)		(3,437	)
Maturities of short-term investments		1,396			–			–
Deposits for investment in partnership entities		(21,491	)		(279,413	)		(40,717	)
Net cash used in investing activities		(68,789	)		(309,602	)		(45,116	)
Cash flows from financing activities:
Proceeds from short-term borrowings		55,000			47,000			6,849
Repayments of short-term borrowings		(31,670	)		(44,000	)		(6,412	)
Payments of offering costs related to followed-on offering		(1,306	)		–			–
Repayments to a related party		(2,300	)		–			–
Advance from a related party		–			1,824			266
Sale of public shares through public offering		43,644			–			–
Sale of ordinary shares through private placement		–			280,000			40,802
Net cash provided by financing activities		63,368			284,824			41,505
Effect of exchange rate changes on cash and cash equivalents		(507	)		(3,455	)		(405	)
Net decrease in cash and cash equivalents		(1,579	)		(19,888	)		(2,799	)
Cash and cash equivalents at the beginning of period		31,661			30,305			4,334
Cash and cash equivalents at the end of period		30,082			10,417			1,535
Supplemental disclosure of cash flow information:
Income tax paid		159			–			–
Interest paid		1,014			1,482			216
Supplemental disclosure of non-cash flow information:
Obtaining right-of-use assets in exchange for lease liability		–			211			31

Costa Mesa, CA, Oct. 07, 2026 (GLOBE NEWSWIRE) — Real Messenger Corporation (“Real Messenger” or the “Company”) (Nasdaq: RMSG), an innovative chat-based platform reimagining real estate connections, today announced that by letter dated October 6, 2026, the staff (the “Staff”) of The Nasdaq Capital Market (“Nasdaq”) notified the Company that, based on the Company’s Form 6-K dated June 10, 2026 and the supplemental information submitted on October 2, 2026, the Staff determined that the Company complies with Listing Rule 5550(b)(1).

As previously disclosed, on April 6, 2026, the Company received written notification from the Staff that it did not comply with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of US$2.5 million.

The Staff further advised the Company that, if the Company fails to evidence compliance with the Rule upon filing its interim financial statements for the period ended September 30, 2026, the Company may be subject to delisting. In that event, the Staff would provide written notification to the Company, and the Company would have the right to appeal the Staff’s determination to a Nasdaq Hearings Panel.

The Company intends to continue monitoring its compliance with all applicable Nasdaq continued listing requirements. Although the Company believes it currently satisfies the stockholders’ equity requirement under Listing Rule 5550(b)(1), there can be no assurance that the Company will continue to satisfy such requirement or any other Nasdaq continued listing standard in the future.

About Real Messenger Corporation

Real Messenger Corporation (Nasdaq: RMSG) is a real estate technology platform headquartered in Costa Mesa, CA. Founded in 2022, Real Messenger is transforming real estate engagement by connecting agents, buyers, sellers, and other industry participants within a unified, social platform. With users across 35 countries, Real Messenger’s primary reach is in the U.S., with notable growth in key markets such as the U.K. and Australia.

With over 1 million users, Real Messenger is building a vibrant global community, creating a dynamic space for real estate connections, insights, and experiences. In recognition of its impact, Real Messenger was named to the 2023 HousingWire Tech 100 list, and its CEO, Thomas Ma, was honored in Inman’s “Best of Proptech” awards in 2023.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should” “would,” “plan,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other performance metrics and projections of market opportunity. These statements are based on various assumptions, whether or not identified in this communication and on the current expectations of Real Messenger’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Real Messenger. Some important factors that could cause actual results to differ materially from those in any forward-looking statements could include changes in domestic and foreign business, market, financial, political and legal conditions.

If any of these risks materialize or Real Messenger’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Real Messenger does not presently know, or that Real Messenger currently believes are immaterial that could also cause actual results to differ from those contained in the forward- looking statements. In addition, forward-looking statements reflect Real Messenger’s current expectations, plans and forecasts of future events and views as of the date hereof. Nothing in this communication should be regarded as a representation by any person that the forward- looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein and the risk factors described in the Company’s Annual Report on Form 20-F for the fiscal year ended March 31, 2026, filed with the SEC on July 28, 2026, as amended, including those under “Risk Factors” therein. Real Messenger anticipates that subsequent events and developments will cause its assessments to change. However, while Real Messenger may elect to update these forward-looking statements at some point in the future, Real Messenger specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Real Messenger’s assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts
Real Messenger Corporation
ir@real.co